Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021 Superior profile of novel anti-tau antibody PRX005 supports advancement for the potential treatment of Alzheimer’s diseaseNew analyses of prasinezumab continue to support potential disease modifying...

Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021 Robust preclinical data support the benefit of PRX005, a novel anti-tau antibody, for the potential treatment Alzheimer’s diseaseNew pre-specified exploratory subgroup analyses and new digital...

Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA Significant survival benefit observed in VITAL study for birtamimab-treated patients with AL amyloidosis at high risk for early mortality (Mayo Stage IV, HR=0.413, p=0.025, over 9 months)SPA agreement...

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Prothena Corporation plc and Encourages Investors who Purchased Shares in the March 2017 Secondary Offering to Contact the Firm LOS ANGELES, March 14, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prothena...